| Nylidrin | hsa00030 | Pentose phosphate pathway | 3.13E-06 | 5 | P60891, P51854, P52209, P11413, P37837 | PRPS1, TKTL1, PGD, G6PD, TALDO1 | More | |
| Nylidrin | hsa00052 | Galactose metabolism | 1.03E-02 | 2 | P06280, O43451 | GLA, MGAM | More | |
| Nylidrin | hsa00053 | Ascorbate and aldarate metabolism | 4.93E-02 | 1 | P14550 | AKR1A1 | More | |
| Nylidrin | hsa00190 | Oxidative phosphorylation | 2.29E-02 | 2 | Q16718, O14521 | NDUFA5, SDHD | More | |
| Nylidrin | hsa00480 | Glutathione metabolism | 1.35E-02 | 1 | P11413 | G6PD | More | |
| Nylidrin | hsa00500 | Starch and sucrose metabolism | 1.67E-02 | 2 | O43451, P06737 | MGAM, PYGL | More | |
| Nylidrin | hsa00531 | Glycosaminoglycan degradation | 4.77E-02 | 1 | P34059 | GALNS | More | |
| Nylidrin | hsa00532 | Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan sulfate | 2.41E-02 | 1 | Q9Y2C2 | UST | More | |
| Nylidrin | hsa00565 | Ether lipid metabolism | 4.93E-02 | 1 | Q8N661 | TMEM86B | More | |
| Nylidrin | hsa00730 | Thiamine metabolism | 5.29E-03 | 2 | P05186, P24666 | ALPL, ACP1 | More | |
| Nylidrin | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | |
| Nylidrin | hsa00983 | Drug metabolism - other enzymes | 2.46E-03 | 3 | P04183, P32320, P05164 | TK1, CDA, MPO | More | |
| Nylidrin | hsa01200 | Carbon metabolism | 2.23E-02 | 4 | P51854, P11413, P37837, P60891 | TKTL1, G6PD, TALDO1, PRPS1 | More | |
| Nylidrin | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | |
| Nylidrin | hsa01523 | Antifolate resistance | 1.68E-02 | 2 | Q92820, P04818 | GGH, TYMS | More | |
| Nylidrin | hsa02010 | ABC transporters | 2.17E-03 | 3 | P45844, P08183, Q8IZY2 | ABCG1, ABCB1, ABCA7 | More | |
| Nylidrin | hsa03010 | Ribosome | 1.88E-02 | 6 | P62753, P25398, P32969, P62829, P18077, P36578 | RPS6, RPS12, RPL9, RPL23, RPL35A, RPL4 | More | |
| Nylidrin | hsa03020 | RNA polymerase | 3.59E-02 | 2 | P30876, P62487 | POLR2B, POLR2G | More | |
| Nylidrin | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | |
| Nylidrin | hsa04064 | NF-kappa B signaling pathway | 1.60E-02 | 8 | P10415, O00463, Q04759, Q9UDY8, Q16548, Q13315, P24522, P09341 | BCL2, TRAF5, PRKCQ, MALT1, BCL2A1, ATM, GADD45A, CXCL1 | More | |
| Nylidrin | hsa04071 | Sphingolipid signaling pathway | 8.25E-05 | 7 | P21453, Q9H228, P01375, Q13362, Q9BX95, P10415, Q9UQC2 | S1PR1, EDG8, TNF, PPP2R5C, SGPP1, BCL2, GAB2 | More | |
| Nylidrin | hsa04080 | Neuroactive ligand-receptor interaction | 2.16E-03 | 9 | P08311, P28472, Q15722, P21453, Q9H228, O00398, P21730, Q16581, P07550 | CTSG, GABRB3, LTB4R, S1PR1, EDG8, P2RY10, C5AR1, C3AR1, ADRB2 | More | |
| Nylidrin | hsa04110 | Cell cycle | 6.63E-04 | 6 | P06493, O60566, P30304, P33981, P42773, P01106 | CDK1, BUB1B, CDC25A, TTK, CDKN2C, MYC | More | |
| Nylidrin | hsa04115 | p53 signaling pathway | 3.98E-02 | 5 | P24522, Q13315, Q53FA7, O95067, P10415 | GADD45A, ATM, TP53I3, CCNB2, BCL2 | More | |
| Nylidrin | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | |
| Nylidrin | hsa04141 | Protein processing in endoplasmic reticulum | 4.88E-02 | 4 | P18848, O60337, P11142, P07900 | ATF4, MARH6, HSPA8, HSP90AA1 | More | |
| Nylidrin | hsa04210 | Apoptosis | 5.05E-03 | 10 | Q13315, P10415, O76075, P01375, Q9NR28, P24522, Q16548, P43234, P18848, Q14643 | ATM, BCL2, DFFB, TNF, DIABLO, GADD45A, BCL2A1, CTSO, ATF4, ITPR1 | More | |
| Nylidrin | hsa04213 | Longevity regulating pathway - multiple species | 2.85E-02 | 2 | Q9Y4H2, Q13547 | IRS2, HDAC1 | More | |
| Nylidrin | hsa04217 | Necroptosis | 4.24E-05 | 10 | P01375, P48023, Q14765, P07900, P15104, P05141, P01584, P0C0S5, Q99878, Q13557 | TNF, FASLG, STAT4, HSP90AA1, GLUL, SLC25A5, IL1B, H2AFZ, H2AC14, CAMK2D | More | |
| Nylidrin | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.95E-02 | 4 | P07550, P22694, P18848, Q13362 | ADRB2, PRKACB, ATF4, PPP2R5C | More | |
| Nylidrin | hsa04340 | Hedgehog signaling pathway | 3.32E-02 | 2 | P49841, P22694 | GSK3B, PRKACB | More | |
| Nylidrin | hsa04610 | Complement and coagulation cascades | 2.33E-03 | 1 | P0C0L4 | C4A | More | |
| Nylidrin | hsa04612 | Antigen processing and presentation | 2.09E-04 | 8 | P13765, P48382, Q14953, P26715, P26717, Q13241, P01732, P01375 | HLA-DOB, RFX5, KIR2DS5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | |
| Nylidrin | hsa04613 | Neutrophil extracellular trap formation | 3.76E-04 | 10 | P11215, Q13547, P04908, Q93077, P58876, Q16778, O60814, P68431, O43315, Q16539 | ITGAM, HDAC1, H2AC4; H2AC8, HIST1H2AC, H2BC5, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, AQP9, MAPK14 | More | |
| Nylidrin | hsa04640 | Hematopoietic cell lineage | 4.95E-02 | 3 | P01730, P06127, P09564 | CD4, CD5, CD7 | More | |
| Nylidrin | hsa04650 | Natural killer cell mediated cytotoxicity | 5.05E-04 | 7 | P01375, P20963, Q13241, P26718, P26717, Q14953, P26715 | TNF, CD247, KLRD1, KLRK1, KLRC2, KIR2DS5, KLRC1 | More | |
| Nylidrin | hsa04657 | IL-17 signaling pathway | 2.73E-04 | 7 | P07900, P49841, P19875, P14780, P80188, P01375, P01584 | HSP90AA1, GSK3B, CXCL2, MMP9, LCN2, TNF, IL1B | More | |
| Nylidrin | hsa04664 | Fc epsilon RI signaling pathway | 2.18E-02 | 2 | P09917, P20292 | ALOX5, ALOX5AP | More | |
| Nylidrin | hsa04668 | TNF signaling pathway | 3.55E-02 | 4 | P01375, P18848, P19875, P14780 | TNF, ATF4, CXCL2, MMP9 | More | |
| Nylidrin | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | |
| Nylidrin | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | |
| Nylidrin | hsa04725 | Cholinergic synapse | 4.83E-02 | 4 | P22694, Q14643, P18848, P10415 | PRKACB, ITPR1, ATF4, BCL2 | More | |
| Nylidrin | hsa04910 | Insulin signaling pathway | 2.35E-02 | 3 | P22694, P06737, P49841 | PRKACB, PYGL, GSK3B | More | |
| Nylidrin | hsa04913 | Ovarian steroidogenesis | 2.54E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | |
| Nylidrin | hsa04915 | Estrogen signaling pathway | 2.96E-02 | 5 | P14780, P22694, P18848, Q14643, P10415 | MMP9, PRKACB, ATF4, ITPR1, BCL2 | More | |
| Nylidrin | hsa04918 | Thyroid hormone synthesis | 3.50E-02 | 3 | P22694, P18848, Q14643 | PRKACB, ATF4, ITPR1 | More | |
| Nylidrin | hsa04919 | Thyroid hormone signaling pathway | 7.11E-03 | 4 | P49841, P22694, O60244, Q9NVC6 | GSK3B, PRKACB, MED14, MED17 | More | |
| Nylidrin | hsa04924 | Renin secretion | 4.04E-02 | 2 | P22694, P07550 | PRKACB, ADRB2 | More | |
| Nylidrin | hsa04926 | Relaxin signaling pathway | 2.41E-02 | 4 | P18848, P22694, P14780, P30679 | ATF4, PRKACB, MMP9, GNA15 | More | |
| Nylidrin | hsa04927 | Cortisol synthesis and secretion | 4.44E-04 | 3 | Q14643, P18848, P22694 | ITPR1, ATF4, PRKACB | More | |
| Nylidrin | hsa04928 | Parathyroid hormone synthesis, secretion and action | 2.13E-02 | 5 | Q14643, P22694, P23771, P18848, P10415 | ITPR1, PRKACB, GATA3, ATF4, BCL2 | More | |
| Nylidrin | hsa04931 | Insulin resistance | 1.94E-02 | 3 | P01375, P49841, P06737 | TNF, GSK3B, PYGL | More | |
| Nylidrin | hsa04932 | Non-alcoholic fatty liver disease | 6.73E-05 | 9 | P01375, P49841, P18848, P48023, P01584, P13073, O15239, Q16718, O14521 | TNF, GSK3B, ATF4, FASLG, IL1B, COX4I1, NDUFA1, NDUFA5, SDHD | More | |
| Nylidrin | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
| Nylidrin | hsa04962 | Vasopressin-regulated water reabsorption | 2.18E-02 | 2 | P52566, P62491 | ARHGDIB, RAB11A | More | |
| Nylidrin | hsa04964 | Proximal tubule bicarbonate reclamation | 4.93E-02 | 1 | P00918 | CA2 | More | |
| Nylidrin | hsa04966 | Collecting duct acid secretion | 4.93E-02 | 1 | P00918 | CA2 | More | |
| Nylidrin | hsa04970 | Salivary secretion | 1.91E-02 | 3 | P07550, P22694, P49913 | ADRB2, PRKACB, CAMP | More | |
| Nylidrin | hsa04976 | Bile secretion | 1.67E-03 | 3 | O43315, P22694, P08183 | AQP9, PRKACB, ABCB1 | More | |
| Nylidrin | hsa05012 | Parkinson disease | 2.53E-02 | 5 | O15239, P13073, P05141, P18848, Q13557 | NDUFA1, COX4I1, SLC25A5, ATF4, CAMK2D | More | |
| Nylidrin | hsa05016 | Huntington disease | 3.21E-02 | 5 | O15239, P13073, P30876, P62487, P05141 | NDUFA1, COX4I1, POLR2B, POLR2G, SLC25A5 | More | |
| Nylidrin | hsa05020 | Prion disease | 3.73E-04 | 11 | P13591, P01584, P11142, O15239, Q16718, O14521, P13073, P18848, P05141, P49841, Q16539 | NCAM1, IL1B, HSPA8, NDUFA1, NDUFA5, SDHD, COX4I1, ATF4, SLC25A5, GSK3B, MAPK14 | More | |
| Nylidrin | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.47E-03 | 12 | P49841, O15239, Q16718, O14521, P13073, P18848, Q13561, P05141, Q16539, P01584, Q08752, Q13557 | GSK3B, NDUFA1, NDUFA5, SDHD, COX4I1, ATF4, DCTN2, SLC25A5, MAPK14, IL1B, PPID, CAMK2D | More | |
| Nylidrin | hsa05031 | Amphetamine addiction | 4.32E-02 | 3 | P22694, P18848, Q13547 | PRKACB, ATF4, HDAC1 | More | |
| Nylidrin | hsa05034 | Alcoholism | 2.10E-03 | 4 | Q13547, P58876, Q16778, O60814 | HDAC1, H2BC5, HIST2H2BE, H2BC12 | More | |
| Nylidrin | hsa05133 | Pertussis | 4.20E-02 | 1 | P0C0L4 | C4A | More | |
| Nylidrin | hsa05134 | Legionellosis | 1.28E-02 | 3 | P01584, P68104, P11142 | IL1B, EEF1A1, HSPA8 | More | |
| Nylidrin | hsa05143 | African trypanosomiasis | 7.50E-04 | 4 | P01375, P69905, P68871, P48023 | TNF, HBA2, HBB, FASLG | More | |
| Nylidrin | hsa05144 | Malaria | 1.44E-03 | 5 | P69905, P68871, P01375, P35443, P26718 | HBA2, HBB, TNF, THBS4, KLRK1 | More | |
| Nylidrin | hsa05146 | Amoebiasis | 2.41E-02 | 4 | P19875, P01375, P30679, P22694 | CXCL2, TNF, GNA15, PRKACB | More | |
| Nylidrin | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | |
| Nylidrin | hsa05162 | Measles | 4.02E-02 | 3 | P11142, P01584, Q9NP90 | HSPA8, IL1B, RAB9B | More | |
| Nylidrin | hsa05171 | Coronavirus disease - COVID-19 | 9.72E-03 | 7 | P01584, P62753, P25398, P36578, P32969, P18077, P62829 | IL1B, RPS6, RPS12, RPL4, RPL9, RPL35A, RPL23 | More | |
| Nylidrin | hsa05202 | Transcriptional misregulation in cancer | 1.63E-03 | 15 | Q15532, Q13315, P14780, P27930, Q15744, Q16548, P11215, O15550, P05164, P12838, P08246, Q9C0K0, Q13547, P12980, P24522 | SS18, ATM, MMP9, IL1R2, CEBPE, BCL2A1, ITGAM, UTX, MPO, DEFA4, ELA2, BCL11B, HDAC1, LYL1, GADD45A | More | |
| Nylidrin | hsa05203 | Viral carcinogenesis | 6.44E-03 | 4 | Q13547, P58876, Q16778, O60814 | HDAC1, H2BC5, HIST2H2BE, H2BC12 | More | |
| Nylidrin | hsa05205 | Proteoglycans in cancer | 3.68E-02 | 5 | P14780, P01375, P23588, Q13635, P22694 | MMP9, TNF, EIF4B, PTCH1, PRKACB | More | |
| Nylidrin | hsa05230 | Central carbon metabolism in cancer | 1.12E-02 | 1 | P11413 | G6PD | More | |
| Nylidrin | hsa05321 | Inflammatory bowel disease | 1.19E-03 | 6 | P01375, P13765, Q14765, Q9UL17, P23771, Q9HBE5 | TNF, HLA-DOB, STAT4, TBX21, GATA3, IL21R | More | |
| Nylidrin | hsa05322 | Systemic lupus erythematosus | 1.18E-02 | 3 | P58876, Q16778, O60814 | H2BC5, HIST2H2BE, H2BC12 | More | |
| Nylidrin | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
| Nylidrin | hsa05332 | Graft-versus-host disease | 1.91E-05 | 6 | P13765, P48023, P10747, P01375, P26715, Q13241 | HLA-DOB, FASLG, CD28, TNF, KLRC1, KLRD1 | More | |
| Nylidrin | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 4.93E-02 | 1 | P54284 | CACNB3 | More | |
| Nylidrin | hsa05415 | Diabetic cardiomyopathy | 3.65E-04 | 9 | P05141, O15239, Q16718, O14521, P13073, Q16539, P49841, Q13557, P11413 | SLC25A5, NDUFA1, NDUFA5, SDHD, COX4I1, MAPK14, GSK3B, CAMK2D, G6PD | More | |
